Publicaciones en colaboración con investigadores/as de University of Antwerp (49)

2024

  1. A genome-wide association meta-analysis of all-cause and vascular dementia

    Alzheimer's and Dementia, Vol. 20, Núm. 9, pp. 5973-5995

  2. A systematic review of progranulin concentrations in biofluids in over 7,000 people—assessing the pathogenicity of GRN mutations and other influencing factors

    Alzheimer's Research and Therapy, Vol. 16, Núm. 1

  3. Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study

    Alzheimer's and Dementia, Vol. 20, Núm. 10, pp. 6722-6739

  4. Blood-based multivariate methylation risk score for cognitive impairment and dementia

    Alzheimer's and Dementia, Vol. 20, Núm. 10, pp. 6682-6698

  5. CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease

    Alzheimer's and Dementia, Vol. 20, Núm. 9, pp. 6205-6220

  6. Extending the phenotypic spectrum assessed by the CDR plus NACC FTLD in genetic frontotemporal dementia

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 16, Núm. 2

  7. Involvement of the choroid plexus in Alzheimer’s disease pathophysiology: findings from mouse and human proteomic studies

    Fluids and Barriers of the CNS, Vol. 21, Núm. 1

  8. Longitudinal cerebral perfusion in presymptomatic genetic frontotemporal dementia: GENFI results

    Alzheimer's and Dementia, Vol. 20, Núm. 5, pp. 3525-3542

  9. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

  10. Paired plasma lipidomics and proteomics analysis in the conversion from mild cognitive impairment to Alzheimer's disease

    Computers in Biology and Medicine, Vol. 176

2023

  1. CanScreen5, a global repository for breast, cervical and colorectal cancer screening programs

    Nature Medicine, Vol. 29, Núm. 5, pp. 1135-1145

  2. Erratum: Author Correction: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores (Nature communications (2021) 12 1 (3417))

    Nature communications

  3. Genetic Associations between Modifiable Risk Factors and Alzheimer Disease

    JAMA Network Open, Vol. 6, Núm. 5

  4. Multiancestry analysis of the HLA locus in Alzheimer's and Parkinson's diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 120, Núm. 36

  5. Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning

    Genome Medicine, Vol. 15, Núm. 1

  6. PFAS levels and exposure determinants in sensitive population groups

    Chemosphere, Vol. 313

  7. Whole-exome rare-variant analysis of Alzheimer's disease and related biomarker traits

    Alzheimer's and Dementia, Vol. 19, Núm. 6, pp. 2317-2331

2022

  1. Association of Rare APOE Missense Variants V236E and R251G with Risk of Alzheimer Disease

    JAMA Neurology, Vol. 79, Núm. 7, pp. 652-663

  2. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease

    Molecular neurodegeneration, Vol. 17, Núm. 1, pp. 27

  3. Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (Molecular Neurodegeneration, (2022), 17, 1, (27), 10.1186/s13024-022-00521-3)

    Molecular Neurodegeneration